Topical cyclosporine 2% for herpetic interstitial keratitis

Randomized controlled trial for evaluation of safety and efficacy of topical cyclosporine 2% versus topical prednisolone for treatment of herpetic interstitial keratitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015052112724N2

Enrollment

Registered

2015-10-28

Start date

2015-05-31

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Herpetic interstitial keratitis. Herpesviral keratitis and keratoconjunctivitis

Interventions

Intervention 1: Group 1: Intervention group, treatment with topical Cyclosporine 2 % (provided by Sinadarou company) 1 gtt every 12 hours. Intervention 2: Group 2: Control group, treatment with topica

Treatment - Drugs

Group 1: Intervention group, treatment with topical Cyclosporine 2 % (provided by Sinadarou company) 1 gtt every 12 hours

Group 2: Control group, treatment with topical prednisolone acetate 1% (Precord, Sinadarou company), 1 gtt every 6 hours

Eligibility

Sex/Gender

All

Age

16 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Diagnosis of herpetic interstitial keratitis, No history of treatment with any form of immunosuppressant drugs one month before intervention, No history of diabetes mellitus, No history of co-existing viral disease. Exclusion criteria: Any side effect attributable to study, patients who have not used drugs regularly, patients who have not come for follow up visits.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Cornea haziness. Timepoint: Before and 1 month after treatment. Method of measurement: Pentacam optical densitometry.	—

Secondary

Measure	Time frame
Visual acuity. Timepoint: Before and 1 month after treatment. Method of measurement: Snellen chart.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mohsen Pourazizi

Isfahan University of Medical Sciences

mr.nayebzade@gmail.com+98 31 3445 2031

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026